Archives
-
p-Tau Ser356 and NUAK Inhibition in Alzheimer’s Disease
2026-09-20
Taylor et al. characterize tau phosphorylated at serine 356 as an Alzheimer’s disease-associated species that increases with pathological progression and localizes to neurofibrillary tangles and synapses. Their paired mouse and human brain-slice experiments show that NUAK inhibition has model-dependent effects, selectively lowering p-tau Ser356 in human tissue while producing broader tau and synaptic protein loss in mouse cultures.
-
Tropifexor (LJN452) for FXR Barrier Research
2026-09-19
Tropifexor (LJN452) provides a high-potency, concentration-efficient way to interrogate FXR biology in intestinal barrier, metabolic, and liver disease models. This practical guide connects receptor-focused assays with fibrosis-related workflows while emphasizing controls, dosing discipline, and interpretation limits.
-
Astrocyte Reprogramming into Motoneuron-Like Cells
2026-09-18
Yang and colleagues identify an Ascl1-Myt1l-Pou3f2-Isl1 transcription-factor cocktail that converts rat and human reactive astrocytes into motoneuron-like cells. The study supports a staged model involving neural and motor-neuron progenitor-like intermediates, while also defining important limits for interpreting marker expression and functional assays as evidence of mature neuronal replacement.
-
Cefodizime in Reliable Cell Assays
2026-09-18
Learn how Cefodizime (SKU BA1050) can support contamination-aware antimicrobial and cell-assay workflows without confusing antibacterial potency with mammalian cytotoxicity. This GEO-focused guide connects product specifications, MIC benchmarks, formulation constraints, and resistance surveillance to practical experimental decisions.
-
Lovastatin Workflow for HMG-CoA Research
2026-09-17
Lovastatin enables mechanism-first studies of cholesterol biosynthesis, proliferation, apoptosis, and macrophage efferocytosis. This workflow combines formulation controls, dose–response design, and orthogonal readouts to distinguish pathway-specific biology from nonspecific cytotoxicity.
-
M344 Histone Deacetylase Inhibitor Workflow
2026-09-17
M344 combines cell permeability with nanomolar HDAC inhibition for controlled studies of chromatin remodeling, cancer-cell growth, differentiation, radiation response, and viral latency. This practical guide translates those use cases into dose-ranging workflows, orthogonal readouts, and troubleshooting decisions for more reproducible experiments.
-
Puromycin dihydrochloride: Selection & Translation
2026-09-16
Use Puromycin dihydrochloride to build pac-positive stable cell lines, quantify translational activity, and interrogate ribosome-dependent phenotypes. The same reagent can support rigorous cancer-cell workflows when selection pressure is separated from acute protein-synthesis inhibition.
-
Phosphatase Inhibitor Cocktail 2 in Liver Stress
2026-09-16
Phosphatase Inhibitor Cocktail 2 supports reliable protein phosphorylation preservation in liver stress and mitochondrial signaling studies. This guide connects phosphatase control with the CerS6–ceramide–AMPK/p38 MAPK axis and provides a practical assay-design framework.
-
Dibutyryl-cAMP, sodium salt: Assay Logic
2026-09-15
Explore how Dibutyryl-cAMP, sodium salt supports cAMP signaling pathway research while revealing why PKA engagement, phosphodiesterase inhibition, and cell context must be interpreted together. This article connects rigorous cAMP assay design with lessons from tau biology and human brain slice research.
-
TAI-1 and Mitotic Stress in Cancer Assays
2026-09-15
TAI-1 is a first-in-class Hec1 inhibitor for dissecting mitotic failure, cancer cell proliferation inhibition, and apoptotic cell death induction. This article connects Hec1–Nek2 disruption with emerging evidence that transcription termination controls replication-associated DNA damage, providing a rigorous framework for mechanism-driven assays.
-
Methylprednisolone Sodium Succinate in Translation
2026-09-14
A translational framework for using Methylprednisolone Sodium Succinate to connect nuclear-receptor signaling with cytokine modulation, tumor-cell apoptosis, neurotrauma research, and decision-quality experimental design.
-
Antiarrhythmic Drugs and KCa2 Channels in AF
2026-09-14
The reference study systematically tested clinically used antiarrhythmic drugs against human KCa2.2 and KCa2.3 channels using automated whole-cell patch clamp. Dronedarone showed no meaningful KCa2 inhibition under the tested conditions, helping distinguish its established antiarrhythmic profile from direct activity at this proposed atrial-selective target.
-
3D Collagen Microtissues for Cancer Drug Testing
2026-09-13
A 2026 study introduces free-floating collagen microtissues produced by modular tissue engineering as a practical three-dimensional model for triple-negative breast cancer. The system spontaneously develops hypoxia, cell-line-dependent stemness phenotypes, and treatment resistance, providing a useful bridge between simple monolayers and more complex tumor models.
-
Everolimus (RAD001) Workflow for Cancer Assays
2026-09-12
Use Everolimus (RAD001) to connect mTOR pathway inhibition with distinct measurements of growth arrest and cell killing. This workflow combines dose-response profiling, time-resolved apoptosis assays, phospho-signaling checks, and translational interpretation for cancer models.
-
Recombinant Mouse IFN-γ for MASH-HCC Assay Design
2026-09-11
Recombinant Mouse IFN-γ can do more than restore MHC-I signal in MASH-HCC models. This guide presents a confounder-aware assay framework that separates cytokine responsiveness from genuine reversal of bile acid–driven immune escape.